Ethyl eicosapentaenoic acid - Amarin

Drug Profile

Ethyl eicosapentaenoic acid - Amarin

Alternative Names: AMR-101; Eicosapentaenoic acid ethyl ester - Amarin; Ethyl eicosapentaenoate; Ethyl eicosopentaenoate; Ethyl icopenate; Ethyl-EPA; Icosapent ethyl; LAX 101c; LAX-101; Miraxion™; Pure EPA; Ultra-pure eicosapentaenoic acid; Ultra-pure EPA; Vascepa

Latest Information Update: 23 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Scarista
  • Developer Amarin Corporation
  • Class Antidepressants; Antihyperlipidaemics; Antiplatelets; Eicosanoids; Esters; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia
  • Discontinued Huntington's disease; Major depressive disorder; Memory disorders; Parkinson's disease; Psychotic disorders

Most Recent Events

  • 03 May 2017 China regulatory authorities approves the clinical trial application for Hypertriglyceridaemia from Eddingpharm
  • 03 May 2017 Eddingpharm plans a clinical trial for Hypertriglyceridaemia in China before the end of 2017
  • 09 Mar 2017 Ethyl eicosapentaenoic acid - Amarin is available for licensing in (excluding USA) as of 09 Mar 2017. http://www.amarincorp.com/default.aspx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top